Andrographis for Immune Modulation

Andrographis is often grouped with classical "immune-stimulant" herbs like echinacea, astragalus, and elderberry, but the molecular reality is more interesting. Andrographolide simultaneously enhances the innate clearance arm of the immune response — activating natural killer (NK) cell cytotoxicity, increasing macrophage phagocytosis, and stimulating dendritic cell antigen presentation — while damping the adaptive cytokine surge that drives autoimmune over-activation. This dual personality is most visible in the Burgos 2009 randomized controlled trial of HMPL-004 (a purified andrographolide-enriched extract) in active mild-to-moderate ulcerative colitis, where the herb produced clinical remission rates comparable to mesalazine without immunosuppression and without the infection risk of biologic anti-TNF therapy. This deep-dive walks through the molecular targets that underlie immunomodulation rather than immune stimulation, the cell-by-cell evidence from in-vitro and animal work, the Burgos UC trial in detail, and the practical applications for patients with autoimmune disease, recurrent infection, or both.

Table of Contents

  1. Modulation vs Stimulation — The Conceptual Difference
  2. Natural Killer (NK) Cell Activation
  3. Macrophage Phagocytosis and Intracellular Killing
  4. CD4+ / CD8+ T-Cell Effects
  5. Th1 / Th2 / Th17 Cytokine Balance
  6. The Burgos 2009 Ulcerative Colitis RCT
  7. HMPL-004 Phase II Follow-up Trial
  8. Other Autoimmune Applications
  9. Recurrent Infection and Adult Immune Restoration
  10. Cautions (Including Transplant and Immunosuppressant Interactions)
  11. Key Research Papers
  12. Connections

Modulation vs Stimulation — The Conceptual Difference

The popular framing of herbs as "immune boosters" obscures an important distinction. Crude immune stimulants (echinacea polysaccharides, some mushroom beta-glucans, bacterial cell-wall preparations) upregulate the entire inflammatory cascade non-selectively — useful when you need a sluggish immune system to mount any response at all, but actively counter-productive in autoimmune and chronic inflammatory disease where the problem is too much immune activation, not too little.

An immune modulator, by contrast, selectively pushes specific arms of the response while damping others. Andrographolide is the canonical example of this in the herbal pharmacopeia. It:

The combination is unusual. The closest pharmaceutical analog is probably abatacept (CTLA-4-Ig, brand name Orencia) — a designed biologic that selectively damps T-cell activation in rheumatoid arthritis without globally suppressing infection-fighting capacity. Andrographolide produces a more nuanced version of the same effect through a small natural-product molecule.

The clinical implication is that Andrographis is not contraindicated in autoimmune disease the way crude immune stimulants like echinacea sometimes are. The Burgos 2009 ulcerative colitis trial discussed below is the clearest demonstration that Andrographis can be safely used in an autoimmune inflammatory condition without producing flare.

Back to Table of Contents

Natural Killer (NK) Cell Activation

Natural killer cells are large granular lymphocytes that constitute the front line of innate cellular immunity. Unlike T cells, they do not require antigen-specific receptor priming — they recognize and lyse "missing-self" cells (cells that have downregulated their normal MHC-I expression as part of malignant transformation or viral infection) using germline-encoded activating receptors (NKG2D, NKp30, NKp46) balanced against inhibitory receptors (KIR family, NKG2A).

NK cells matter clinically because they are the principal early defense against intracellular viral infection (herpes family, hepatitis, influenza) and the principal early defense against newly transformed tumor cells. Patients with NK cell deficiency syndromes have severe, often fatal, recurrent herpes virus infections and elevated cancer risk — powerful evidence of the day-to-day importance of NK function.

Andrographolide has been shown in multiple cell-culture and animal-model studies to:

The clinical translation to human patients has been studied less extensively than the cellular work would warrant, but pilot trials in older adults and immunocompromised patients (HIV-positive, post-chemotherapy) have shown modest restoration of NK function after a few weeks of standardized Andrographis extract intake. This is a candidate explanation for some of the observed protective effect against viral URTI — not just direct antiviral binding to the virus, but enhanced cellular clearance of infected cells.

Back to Table of Contents

Macrophage Phagocytosis and Intracellular Killing

Macrophages are the long-lived tissue-resident phagocytes that constitute the second front line of innate immunity (after the more nimble but shorter-lived neutrophil). Pulmonary alveolar macrophages, Kupffer cells in the liver, microglia in the brain, and osteoclasts in bone are all specialized macrophage populations performing site-specific defense and tissue-housekeeping functions. Macrophage function depends on two related capacities: phagocytosis (engulfment of particles, dying cells, and microbes) and intracellular killing (reactive oxygen species production via NADPH oxidase, nitric oxide production via iNOS, lysosomal acidification and proteolysis).

Andrographolide effects on macrophages are dose- and context-dependent:

This dose-and-context-dependent profile is the essence of immunomodulation rather than immunostimulation. The herb increases macrophage clearance function when challenged but does not provoke a futile inflammatory storm when there is no pathogen to engage.

Back to Table of Contents

CD4+ / CD8+ T-Cell Effects

The ratio of CD4+ helper T cells to CD8+ cytotoxic T cells in peripheral blood is one of the most useful crude measures of cellular immunity. A normal CD4/CD8 ratio is roughly 1.5-2.5. Ratios below 1.0 (CD4 lymphopenia) indicate compromised cellular immunity, classically seen in advanced HIV, chemotherapy, post-organ-transplant, malnutrition, and chronic stress. Ratios above 4.0 (CD8 lymphopenia) can indicate autoimmune disease, chronic viral infection, or immunosenescence.

Small pilot trials of standardized Andrographis extract (and andrographolide-enriched fractions) in HIV-positive patients in the 1990s-2000s reported modest restoration of CD4 counts and CD4/CD8 ratios toward normal values. The effects were small relative to combination antiretroviral therapy (which can fully reconstitute CD4 counts) and Andrographis is not recommended as primary HIV therapy — but the signal was real and is consistent with the broader immunomodulatory profile.

In immunocompetent adults with no underlying lymphocyte abnormality, Andrographis does not appreciably change baseline CD4/CD8 ratios. This is again characteristic of true immunomodulation — the herb pushes the system toward normal where there is abnormality but does not perturb a healthy steady-state.

Back to Table of Contents

Th1 / Th2 / Th17 Cytokine Balance

Beyond simple CD4 quantitation, the functional subtype of CD4+ T cells matters enormously. Naive CD4+ T cells encountering antigen differentiate down one of several distinct paths based on local cytokine milieu:

Andrographolide tilts the differentiation balance in context-specific ways. In viral infection (where Th1 is the desired phenotype for intracellular pathogen clearance), andrographolide enhances Th1 differentiation. In allergic and parasitic contexts where excess Th2 drives pathology, andrographolide modestly suppresses Th2 cytokines. In autoimmune contexts where Th17 drives tissue damage (rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease), andrographolide preferentially suppresses Th17 differentiation while supporting Treg expansion. The molecular mechanism involves inhibition of STAT3 phosphorylation (a key Th17 transcription factor) and of NF-kB-driven IL-6 production (a key Th17-polarizing cytokine).

This Th17-suppressing, Treg-supporting profile is the molecular underpinning of Andrographis efficacy in autoimmune disease and is shared with several pharmaceutical agents being developed for the same indications — including the IL-17 antagonists secukinumab and ixekizumab (approved for psoriasis, ankylosing spondylitis, psoriatic arthritis), the IL-23 antagonists guselkumab and risankizumab, and the JAK inhibitors tofacitinib and upadacitinib. Andrographolide is a small natural-product molecule reaching similar therapeutic territory by a different route.

Back to Table of Contents

The Burgos 2009 Ulcerative Colitis RCT

The most clinically important demonstration of Andrographis immunomodulation in a real human disease comes from the Burgos and colleagues 2009 randomized double-blind placebo-controlled trial of HMPL-004 (a proprietary andrographolide-enriched Andrographis extract developed by Hutchison MediPharma) in patients with mild-to-moderate active ulcerative colitis. The trial enrolled 224 patients across multiple Chinese and Indian centers, randomizing them to:

The primary outcome was clinical response (reduction in modified Mayo Clinic disease activity score) at week 8. Secondary outcomes included clinical remission (Mayo score ≤2 with no individual subscore >1), mucosal healing on flexible sigmoidoscopy, and patient-reported quality of life.

Results:

The remission and response rates produced by HMPL-004 in this trial are clinically comparable to the standard-of-care mesalazine (5-ASA) for the same disease severity, which typically produces 30-50% remission rates in 8-week mesalazine trials. This is the strongest single piece of evidence that Andrographis is a real disease-modifying agent in an autoimmune-spectrum disease, not merely a symptom-relief herb.

It is worth noting that HMPL-004 is an andrographolide-enriched extract more concentrated than typical over-the-counter Andrographis products. The 1,200 mg daily dose of HMPL-004 corresponds to a much higher andrographolide intake than would be achieved with the same milligram dose of standard 4-10%-standardized extract. Patients wishing to replicate the HMPL-004 results with available retail Andrographis should look for high-andrographolide-content extracts (10% or higher total andrographolides) and may need to use the higher end of the typical dosing range.

Back to Table of Contents

HMPL-004 Phase II Follow-up Trial

A larger Phase II follow-up trial of HMPL-004 in mild-to-moderate ulcerative colitis was conducted across centers in the US, Europe, China, and India, enrolling over 200 patients with longer follow-up. The follow-up trial confirmed the original Burgos 2009 results: clinical remission rates of 21-26% on Andrographis vs 13-14% on placebo, with mucosal healing rates significantly higher in the Andrographis arms. Tolerability remained excellent.

HMPL-004 development was eventually slowed by commercial rather than scientific factors — the unusual challenge of developing a botanical extract through the standard pharmaceutical regulatory pathway, combined with the rise of biologic anti-TNF and anti-integrin therapies (infliximab, adalimumab, vedolizumab) that addressed moderate-to-severe disease more effectively than HMPL-004 had targeted. The HMPL-004 trial program nevertheless remains a touchstone example of how an evidence-based botanical can match standard pharmaceutical efficacy in an autoimmune indication.

Back to Table of Contents

Other Autoimmune Applications

Beyond the well-documented ulcerative colitis application, Andrographis has been investigated in several other autoimmune-spectrum diseases with varying levels of evidence:

For autoimmune disease applications generally, Andrographis is best used as an adjunct to (not a replacement for) conventional disease-modifying therapy. Its role is in the more nuanced day-to-day inflammation control, while the conventional DMARDs handle the heavy lifting of long-term disease progression prevention.

Back to Table of Contents

Recurrent Infection and Adult Immune Restoration

The other side of the immunomodulation coin is patients with recurrent infection that does not respond well to crude immune stimulants. This includes adults with:

For these patients, a course of Andrographis (typically 600-1,200 mg standardized extract daily for 6-12 weeks) may produce measurable restoration of NK function, modest reduction in infection frequency, and improvement in subjective energy and stamina. The trial database is small and the effect is modest, but tolerability is excellent and the mechanism (NK and macrophage clearance enhancement combined with downregulation of chronic inflammatory cytokines) is plausible.

For patients with frank lymphocyte deficiencies or chronic viral infection requiring antiviral therapy, Andrographis is supportive rather than primary — the underlying condition needs separate management.

Back to Table of Contents

Cautions (Including Transplant and Immunosuppressant Interactions)

Back to Table of Contents

Key Research Papers

  1. Burgos RA, Hancke JL, Bertoglio JC, et al. (2009). Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clinical Rheumatology. — PubMed
  2. Sandborn WJ, Targan SR, Byers VS, et al. (2013). Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. American Journal of Gastroenterology. — PubMed
  3. Tang T, Targan SR, Li ZS, et al. (2011). Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis — a double-blind comparison with sustained-release mesalazine. Alimentary Pharmacology & Therapeutics. — PubMed
  4. Iruretagoyena MI, Tobar JA, Gonzalez PA, et al. (2005). Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. Journal of Pharmacology and Experimental Therapeutics. — PubMed
  5. Kumar RA, Sridevi K, Kumar NV, et al. (2004). Anticancer and immunostimulatory compounds from Andrographis paniculata. Journal of Ethnopharmacology. — PubMed
  6. Sheeja K, Kuttan G (2007). Activation of cytotoxic T lymphocyte responses and attenuation of tumor growth in vivo by Andrographis paniculata extract and andrographolide. Immunopharmacology and Immunotoxicology. — PubMed
  7. Wang T, Liu B, Zhang W, et al. (2004). Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. Journal of Pharmacology and Experimental Therapeutics. — PubMed
  8. Carretta MD, Alarcon P, Jara E, et al. (2009). Andrographolide reduces IL-2 production in T-cells by interfering with NFAT and MAPK activation. European Journal of Pharmacology. — PubMed
  9. Hidalgo MA, Hancke JL, Bertoglio JC, Burgos RA (2013). Andrographolide a new potential drug for the long term treatment of rheumatoid arthritis disease. Innovative Rheumatology. — PubMed
  10. Calabrese C, Berman SH, Babish JG, et al. (2000). A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytotherapy Research. — PubMed
  11. Kumar S, Singh B, Bajpai V (2021). Andrographis paniculata (Burm. f.) Nees: traditional uses, phytochemistry, pharmacological properties and quality control / quality assurance. Journal of Ethnopharmacology. — PubMed
  12. Mussard E, Cesaro A, Lespessailles E, et al. (2019). Andrographolide, a natural antioxidant: an update. Antioxidants. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents